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ABSTRACT
Objective: Autoimmune thyroid disease is one of the organs specific autoimmune disorders. The onset is much more common in women than 
in men. Worldwide, 2–4% of women and only 1% of men have affected and the rate increases with age. Thyroperoxidase (TPO) antibodies (Abs) 
level helps to diagnose autoimmune thyroid disease along with levels of thyroid stimulating hormone (TSH), Free Tri-iodotyrosine (Free T3), and 
Free Thyroxin(Free T4) and it helps in differentiation between subclinical and overt thyroidism. The core objective of clinical study was to evaluate 
prevalence of anti-TPO Abs in association to autoimmune thyroid disease in a tertiary care hospital – Punjab.
Methods: A cross-sectional study of random patient (n=200 patients) at a tertiary care hospital, Mohall – Punjab was carried out. All the patients fall 
in the age group 12–89 years. The parameters, which were used for the diagnosis of autoimmune thyroid disease, were anti-TPO level, Free T3 level, 
and Free T4 level. The patients were divided in different group on the basis of their age, gender, and their clinical conditions. The level of TPO Abs, 
TSH, Free T3, and Free T4 was noted for each patient. Electrochemiluminescence immunoassay method was used for determination of TPO Abs and 
other thyroid parameters. After a period of 16 weeks, subjects from different groups had great difference in their anti-TPO values in the autoimmune 
thyroid disease.
Results: TPO Abs positive is one of the most common associated with hypothyroidism which was 36.5%, among them 20.5% suffered from subclinical 
hypothyroidism, whereas other remaining suffered from clinical hypothyroidism, clinical hyperthyroidism, and other autoimmune disease.
Conclusion: TPO Abs level helps to diagnose autoimmune thyroid disease, along with this the level of TSH, Free T3, and Free T4 helps in differentiation 
between subclinical and overt thyroidism.
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INTRODUCTION
The thyroid gland contains numerous follicles, which are composed 
of epithelial follicular cells and colloid, is an endocrine gland 
located in the neck region in front of the larynx and trachea [1]. It 
references in Western medicine first time in 1656, when it was 
thought that the main function of the thyroid gland was to lubricate 
the trachea [2]. The master gland, maintenance, and regulation of 
metabolic processes throughout the body and adverse effect on under 
and over production of hormones, synthesizes tri-iodotyrosine (T3), 
tetra-iodotyrosine (T4), and thyroid-stimulating hormones (TSH) and 
regulated by feedback inhibition mechanism of hypothalamus [3]. 
One of the major endocrine diseases is autoimmune thyroid disease 
(ATD) in which immune system produces antibodies (Abs) against 
body’s own thyroid cells, that is, thyrocytes and causes inflammation 
of the gland [4].
The autoimmune endocrinal disease is characterized by the 
presence of high titers of Abs such as thyroperoxidase Abs (TPO) 
and thyroglobulin Abs produced by our own body system. These 
Abs damage the thyrocytes and causes inflammation of the thyroid 
gland. The onset is much more common in women, 2–4% women 
and only 1% of men are affected and this rate increases with the 
age [5,6].
Hereditary factors due to genetic alteration and environmental 
and endogenous factors such as advancing age, smoking, iodine 
overconsumption, adverse effects of medication, and hormonal changes 
(females) are key factors of Autoimmune thyroid disease [7,8].
The most common Abs measured in serum sample are thyroglobulin 
and TPO Abs [9]. Due to more specificity in the diagnosis of ATD, 
anti-TPO Abs are preferred along with results of TSH, Free T3, 
and T4. Free T3 measurements support the differential diagnosis 
of thyroid disorders which are needed to distinguish different 
forms of hyperthyroidism and to identify patients with T3 
thyrotoxicosis [10,11]. The determination of Free T4 is helpful 
for monitoring thyrosuppressive therapy [12,13]. Moreover, 
TSH is a very sensitive and specific parameter for assessing 
thyroid function and is particularly suitable for early detection or 
exclusion of disorders in the central regulating circuit between the 
hypothalamus, pituitary, and thyroid [14-17]. The TSH level varies in 
hypothyroidism and hyperthyroidism.
On the basis of laboratory results of anti-TPO Abs, TSH level, 
thyroid hormones level, we can differentiate between euthyroidism, 
subclinical thyroidism, and clinical or overt thyroidism. In case of 
euthyroidism, the level of anti-TPO Abs, TSH, Free T3, and Free T4 
remains normal. In subclinical thyroidism, the level of Anti-TPO Abs 
and TSH increases but Free T3 and Free T4 remains normal. This is 
asymptomatic and only mild impairment occurs in the thyroid gland. 
If it remains, untreated, it will switch over to clinical thyroidism. 
Subclinical thyroidism is much more common than overt thyroidism, 
so early diagnosis and treatment may prevent the onset of overt 
thyroidism and its associated effects [18]. Level of anti-TPO Abs, TSH 
markedly increases, and thyroid hormones will increase or decrease 
according to hyperthyroidism or hypothyroidism, respectively, in 
overt thyroidism. Overt or clinical thyroidism is symptomatic and it 
may cause further complications such as depression and unexplained 
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weight gain. Hashimoto and Grave’s thyroid disease is the most 
common examples of clinical thyroidism.
The study by Silva et al., conducted in 89 Brazilian women, has 
noted elevated anti-TPO levels in around 90% of the patients with 
autoimmune thyroiditis [19]. Lock et al. have highlighted the importance 
of considering anti-TPO antibody testing as an integral part of the 
clinical investigation for subclinical hypothyroidism [20]. In a study 
conducted during the period of 2007–2010 in Delhi, the percentage of 
TPO antibody-positive adults were found to be 13.3% [21]. Similarly, 
an apparent rise in prevalence was noted in the southern part of India. 
The corresponding prevalence of anti-TPO positivity noted in two 
different studies conducted in Kerala and Chennai was 16.7% and 
25.81% [18,22]. A study by Jeena et al. has concluded on the usefulness 
of anti-TPO antibody estimation in establishing the etiological diagnosis 
of autoimmune thyroid diseases. The study has found that out of 
47 hypothyroid subjects evaluated, 28 (60%) had an elevated TPO 
antibody titer [23]. This study is not sufficient because of limitation of 
the studies in the country and further research has been recommended 
by some authors to identifying the autoimmune thyroid disease and 
their changing patterns. The present clinical study was done to check 
prevalence of anti-TPO Abs in association with autoimmune thyroidism 
in a tertiary care hospital – Punjab region.
METHODS
The present clinical study was conducted in a tertiary care hospital, 
Mohali in Punjab region. This study was carried over a period of four 
months from January 2, 2017, to April 30, 2017.
Clinical data were collected from 200 random of males and females, 
of these 80 were males and 120 were female. Age range was 12–89 
years for both males and females. UHID of the patient, level of anti-TPO 
antibody Titer, TSH level, Free T3, and Free T4 level was noted down. 
Then differentiation was done on the basis of age groups, gender 
basis, etc. For serum sample was collected in Yellow Top with SST gel. 
Electrochemiluminescence immunoassay method was used for testing.
Positive autoimmune thyroidism was ascertained when the anti-TPO 
antibody level was >35 U/L Table 1.
Statistical analysis
Results of the study are presented as average, ranges, and percentage 
as per requirements. The values presented in the form of average and 
based on different age groups, presented in percentage form. Ranges 
given of all parameters included for study. All the data were calculated 
in Microsoft Excel 2010 and presented graphically.
RESULTS AND DISCUSSION
Age-wise distribution
Two hundred patients were studied in this clinical study. The mean 
age of total population was 44.67±17.87 (mean±SD) years with range 
12–89 years. The study was divided in four different groups on the basis 
of age factor.
Number of patients in age groups: Group-1, Group-2, Group-3, and 
Group-4 were 10, 62, 100, and 28, respectively, with percentage of 
5%, 31%, 50%, and 14%. Table 2 shows differentiation of different 
age groups as per positivity of anti-TPO Abs and their percentage. The 
prevalence of TPO-Abs positivity in the total population was 1.5%, 
10%, 20.5%, and 4.5% in the Group-1, Group-2, Group-3, and Group-4, 
respectively. During the study, it was observed that the patients within 
the age Group-3 (20.5%) were more prone to autoimmune thyroid 
disease. The advancing age and high TSH level could be a risk factor 
for ATD.
Swain et al. have reported that most of the patients with autoimmune 
thyroid disease were mainly belonging to the age group of 30–50 
years [5]. In our study, age group of 35–65 years found the highest 
number antibody positivity which is very similar to the Swain et al. This 
study showed that TPO positivity increased with the aging of people. 
In aging, there might be an absence of thyroid cysts: Might possess 
beneficial influence on thyroid hormone synthesized by pooling 
thyroglobulin. In the absence of thyroid cyst will affect the production 
of thyroid hormone.
Out of 200 patients, 73 patients showed a positive titer for anti-TPO Abs. 
Hence, 36.5% patients suffered from autoimmune thyroid disease. The 
average anti-TPO Abs level in 73 patients was 258.67U/L and ranged 
from 37.62 to 660U/L Table 3. The average TSH level was 12.72 µIU/
ml and ranged from 0.005 to 65.97 µIU/ml. In the study, we found the 
anti-TPO Abs level higher in Group-2 which is age group in 18–34 years.
Atluri et al. study found that anti-TPO Abs was more prevalent in the 
20–40 age groups [24]. Sindhu et al. found the highest mean value of 
anti-TPO Abs in the 35–44 years age group in Kerala [25]. Our study and 
Atluri et al. finding are similar, however, Sundhu et al. finding are some 
difference. This difference finding maybe due to their sample size or 
may be how they differentiate their population group.
Table 2: Distribution of age groups
Age group Average age mean±SD (years) No. of patients %of total TPO positive (%)
Group – 1 (12–17 years) 14.4±2.31 10 5% 3 (1.5)
Group – 2 (18–34 years) 28.19±3.77 62 31% 20 (10)
Group – 3 (35-65 years) 49.51±9.04 100 50% 41 (20.5)
Group – 4 (>65 years) 74.67±6.04 28 14% 9 (4.5)
Total 200 100 73 (36)
Sample size(n)=200, SD: Standard deviation, TPO: Thyroperoxidase
Table 1: Normal range of parameter
S. No Name Reference range
1 Anti-TPO Abs 5–35 IU/L.
2 TSH 0.27–4.20 uIU/ml
3 Free T3 2.0–4.4 pg/ml
4 Free T4 0.93–1.71 ng/dl
Anti-TPO Abs: Anti-thyroperoxidase antibodies, TSH: Thyroid-stimulating 
hormones, T3: Tri-iodotyrosine, T4: Tetra-iodotyrosine
Table 3: Mean value of TPO Abs, TSH, Free T3, and FreeT4 in various age groups
Age group Anti-TPO Abs (u/ml) TSH (µiu/ml) Free T3 (pg/ml) Free T4 (ng/ml)
Group – 1 (12–17 years) 327.93 28.09 2.41 0.99
Group – 2 (18–34 years) 281.08 10.68 3.23 1.27
Group – 3 (35–65 years) 255.45 14.02 2.81 1.10
Group – 4 (>65 years) 225.04 6.26 3.26 1.16
Anti-TPO Abs: Anti-thyroperoxidase antibodies, TSH: Thyroid-stimulating hormones, T3: Tri-iodotyrosine ,T4: Tetra-iodotyrosine
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Gender-wise distribution
Out of 200 patients, 60% were female patients whereas 40% were male 
patients. The mean age of male patients was 46.5±19.9 years whereas 
for female patients mean age was 43.8±16.9 years.
Out of 73 patients having positive TPO Abs, 22 were male and 51 were 
female patients Table 4. Prevalence of TPO Abs was 11% and 25.5%, 
respectively, in male and female population. In our observation, women 
were more as compared to the men suffering from autoimmune thyroid 
disease and the number of females was more as compared to the men 
in the data.
From above results, female shows more prevalence towards 
autoimmune thyroid diseases as the number of females are more as 
compared to male population and positivity of anti-TPO Abs is also 
more in female Table 5.
The prevalence of TPO-Ab positivity in the total population was 11.9, 
14.9, and 13.6% in the young, middle age, and elderly, respectively [26]. 
Swain et al. have also found that the patients with autoimmune thyroid 
disease were more women than men [5]. These previous studies and 
our study verify the AITD is more prevalence in female than male 
National Health and Nutrition Examination Survey III reported that 
over 10% of adults were TPO-Ab or Tg-Ab positive, with a prevalence of 
13% for TPO-Ab and 11.5% for Tg-Ab [27]. A study by Atieh Amouzegar 
et al. (2016) results about 5783 participants, of which 742 (12.8%) 
were TPO-Ab positive, with the higher prevalence among women than 
in men.
Differential study on the basis of type of Thyroid disease
Seventy-three patients out of 200 were shown positive titer for TPO Abs 
out of 73 positive TPO Abs patients following:
•	 Fo u r t y- o n e  p a t i e n t s  we re  s u f fe r i n g  f ro m  s u b c l i n i c a l 
hypothyroidism having high TPO Abs and TSH level but normal 
Free T3 and T4 level
•	 Sixteen patients were suffering from clinical or overt hypothyroidism 
having high levels of TPO Abs, TSH, and low levels of free thyroid 
hormones
•	 Seven patients were suffering from clinical hyperthyroidism having 
high levels of TPO Abs, TSH and free thyroid hormones
•	 Nine patients showed high level of TPO Abs but normal level of TSH, 
Free T3, and Free T4. This seems to be having other autoimmune 
response toward thyroid Abs or may be due to some another reason. 
That is why, Only TPO Abs titer is high and rest parameters are 
normal.
Rest 127 out of 200 patients showed a normal TPO Abs level with normal 
TSH, Free T3, and Free T4 level. Hence, these patients considered under 
euthyroidism condition.
Percentage wise: 63.5% population were under euthyroidism 
condition, having normal parameters of thyroid profiles and TPO Abs. 
Out of 36.5% patients suffering from autoimmune thyroid disease, 
20.5% were suffering from subclinical hypothyroidism, 8% from overt 
hypothyroidism, 3.5% were suffering from clinical hyperthyroidism, 
and 4.5% patients were suffering from the other autoimmune 
condition. Table 6 shows about a differential study on the basis of 
thyroid disease.
The mean level for TPO Ab, TSH, Free T3 and, Free T4 in Euthyroidism 
was 11.68 U/L, 3.894 µIU/ml, 2.82 pg/ml, and 1.27 ng/ml, respectively. 
In the case of subclinical hypothyroidism, the mean level of TPO Abs, 
TSH, Free T3, and Free T4 was 242.56 U/L, 11.46 µIU/ml, 2.88 pg/ml, 
and 1.12 ng/ml, respectively. In clinical hypothyroidism, the mean level 
is 348.33 U/L, 25.97 µIU/ml, 2.14 pg/ml, and 0.7 ng/ml, respectively, 
for TPO Abs, TSH, Free T3, and Free T4. The mean for clinical 
hyperthyroidism is 145.84, 3.63, 4.7, and 1.93, respectively. About 
4.5% of patients were seemed to be having other autoimmune thyroid 
conditions having mean TPO Abs level 284.98 and 1.99, 3.47, and 1.36, 
respectively, for TSH, Free T3, and Free T4 level.
Around 20.5% of the total patients were suffering from subclinical 
hypothyroidism having high levels of TPO Abs and TSH with normal 
levels of free thyroid hormones. Gupta et al. found that 28.9% 
prevalence of subclinical hypothyroidism [28]. This difference may 
be due to the simple size, type of patient they observed and the 
parameters they applied for identifying disease. Anti-TPO is a more 
promising marker for ATD than other parameters. Others various 
research and study have explained that the prevalence of subclinical 
hypothyroidism is from 4% to 22% [29-32] which is similar to our 
finding of the study.
Subclinical hypothyroidism is a common condition. The prevalence is 
3–8%, increasing with age and being more common in women. After 
the sixth decade, the combined prevalence in both men and women 
is around 10%. About 80% of these patients have a serum TSH of 
<10 mIU/L, and 80% have anti-thyroid Abs [33]. In case of subclinical 
thyroidism patient does not show proper sign and symptoms, but there 
are mild increase levels of TSH and anti-TPO but within normal level of 
Free T3 and Free T4.
Subclinical hypothyroidism may progress to overt hypothyroidism in 
approximately 2–5% cases annually. Subclinical hypothyroidism is 
more common than overt condition so early diagnosis and treatment 
helps to prevent the onset of overt condition and its adverse effects 
on body systems [34]. Patients having high titers of anti TPO are more 
prone to changes in overt condition and it will be more symptomatic.
Table 6: Differential study on the basis of autoimmune thyroid disease condition








Mean Free T3 
level
Mean Free T4 
level
1 Euthyroidism 123 63.5% 11.68 3.894 2.82 1.27
2 Subclinical hypothyroidism 41 20.5% 242.56 11.46 2.88 1.12
3 Clinical/overt hypothyroidism 16 8% 348.33 25.97 2.14 0.7
4 Clinical hyperthyroidism 7 3.5% 145.84 3.63 4.7 1.93
5 Other autoimmune conditions 9 4.5% 284.98 1.99 3.47 1.36
Sample size(n)=200, Anti-TPO Abs: Anti-thyroperoxidase antibodies, TSH: Thyroid-stimulating hormones, T3: Tri-iodotyrosine ,T4: Tetra-iodotyrosine
Table 4: Gender-wise distribution and TPO antibodies
Gender No. of patients Total (%) TPO Ab+ % positivity
Male 80 40 22 11
Female 120 60 51 25.5
Total 200 100 73 36.5
Sample size (n)=200, TPO Abs: Thyroperoxidase antibodies
Table 5: Mean level of TPO Abs, TSH, Free T3, and Free T4 in male 
and female




Free T3  
(ng/dl)
Free T4  
(pg/ml)
Male 258.82 13.14 3.16 1.20
Female 262.94 12.54 2.88 1.11
Anti-TPO Abs: Anti-thyroperoxidase antibodies, TSH: Thyroid-stimulating 
hormones, T3: Tri-iodotyrosine ,T4: Tetra-iodotyrosine
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CONCLUSION
In the current study, of 200 participants, 73 (36.5%) were TPO Abs 
positive, with higher prevalence among women (25.5%) than in men 
(11%). The prevalence of TPO-Abs positivity in the total population 
was 1.5%, 10%, 20.5%, and 4.5% in Group-1, Group-2, Group-3, and 
Group-4, respectively. About 63.5% population showed normal results 
of TPO Abs, TSH, Free T3, and Free T4, so they had euthyroidism 
conditions. About 20.5% suffered from subclinical hypothyroidism, 8% 
of patients suffered from clinical hypothyroidism, 3.5% suffered from 
clinical hyperthyroidism, and 4.5% patients had a high level of TPO Abs 
but normal levels of other thyroid parameters probably had some other 
clinical conditions or autoimmune diseases related to the thyroid gland. 
Gender, age, and elevated serum TSH were found to be risk factors for 
developing TPO Abs positivity.
The TPO Abs level helps in diagnoses the autoimmune thyroid disease 
along with the level of TSH, Free T3, and Free T4 and differentiation 
between subclinical and overt thyroidism.
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